Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors.

< BACK TO ARCHIVE


Papers: 9 Jul 2022 - 15 Jul 2022


Human Studies


2022 Jul 12


J Neurol


http://www.ncbi.nlm.nih.gov/pubmed/35829760?dopt=Abstract

Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors.

Authors

Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors.
Gonzalez-Martinez A, Guerrero-Peral Á L, Arias-Rivas S, Silva L, Sierra Á, Gago-Veiga A B, García-Azorín D
J Neurol. 2022 Jul 12.
PMID: 35829760.

Abstract

Headache is one of the most frequently reported symptoms in post-COVID patients. The clinical phenotype of COVID-19 headache combines phenotypic features of both tension-type headache (TTH) and migraine. We aimed to assess the effectiveness, side effects and predictors of amitriptyline (AMT) response in a real-world study setting.
Read This Paper